New drug combo aims to slow kidney disease
NCT ID NCT06221059
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This completed Phase 2 trial tested two drugs, HRS-1780 and henagliflozin, in 181 adults with chronic kidney disease. Participants took the drugs or placebos for 13 weeks to see if the drugs could reduce protein in the urine, a sign of kidney damage. The study aimed to find a new way to help control the disease.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
HRS-1780 tablet and henagliflozin proline tablet
What this could lead to
If successful, this could point toward a new treatment option to slow kidney damage in chronic kidney disease patients.
What could go wrong
This is an early Phase 2 trial with only 181 participants, so results may not apply to everyone. The drugs may not show meaningful benefit over placebo.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC KIDNEY DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
General Hospital of Eastern Theater Command
Nanjing, Jiangsu, 210002, China